Inhixa

Inhixa is an anticoagulant medicine (a medicine that prevents blood clots) used in adults for: • preventing venous thromboembolism (blood clots that form inside the veins, obstructing blood flow), especially in patients who are having surgery or who are at greater risk of clots because they are beridden due to illness; • treating deep vein thrombosis (DVT, where the clot develops in a deep vein, usually in the leg) and pulmonary embolism (PE, a clot in a blood vessels supplying the lungs); • treating DVT and PE in patients with active cancers, and preventing these clotting problems from occurring again; • treating unstable angina (a severe type of chest pain caused by problems with the blood flow to the heart); • treating certain types of myocardial infarction (heart attack); • preventing clots forming when blood is circulated through a haemodialysis machine to remove toxic substances. In the treatment of unstable angina and heart attack Inhixa is given with aspirin (acetylsalicylic acid). Inhixa contains the active substance enoxaparin sodium and is a ‘biosimilar medicine’. This means that Inhixa is highly similar to another biological medicine (the ‘reference medicine’) that is already authorised in the EU. The reference medicine for Inhixa is Clexane. For more information on biosimilar medicines, see here.